Thrombocytopenia in HIV-infected drug users in the HAART era

Ximena Burbano, Maria Jose Miguez, Robert Lecusay, Allan Rodriguez, Phillip Ruiz, Guillermo Morales, Gloria Castillo, Marianna Baum, Gail Shor-Posner

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


The present case-control study compared 26 HIV+ drug users having persistent thrombocytopenia (TCP<150 000/mm3) with 54 available age, gender and HIV CDC classification matched controls with normal platelet counts. Participants were followed longitudinally over a 2-year period (1998-2000), and hematological alterations evaluated in relationship to antiretroviral treatment, drug use and nutritional (selenium) status. Demographic information and medical history, including antiretroviral treatment were obtained. Blood was drawn for complete cell blood count, T lymphocytes and viral load. Sixty-nine percent of the individuals with persistent TCP and 49% of the controls were receiving antiretrovirals. At baseline, no significant differences in CD4 existed between the two groups. Over time, CD4 cell count declined in the cases (P = 0.05) and a significantly higher proportion of the cases (38%) developed AIDS (CD4<200 cell/mm3), as compared to the controls (18%, P = 0.004). A high risk for development of thrombocytopenia was observed with specific drug use (heroin 2.96 times, P = 0.0007), selenium levels below 145 μg/l (6 times, P = 0.008), and abnormal liver enzyme (SGOT) levels (2 times, P = 0.002). Together, these results indicate a number of factors that may be sensitive predictors of thrombocytopenia, which, despite antiretroviral treatment, appears to be related to more rapid disease progression in drug users.

Original languageEnglish (US)
Pages (from-to)456-461
Number of pages6
Issue number8
StatePublished - 2001

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Thrombocytopenia in HIV-infected drug users in the HAART era'. Together they form a unique fingerprint.

Cite this